MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter
Rhea-AI Summary
MDB Capital Holdings (NASDAQ: MDBH) provided a 2025 full-year update and shareholder letter on March 31, 2026, detailing asset positions, cash, expenses, and strategic spin-outs.
Key points: an EXOZ stake valued at ~$30 million, Paulex seed funding of $19 million, year-end cash of ~$22.3 million, annual fixed operating expenses of ~$10 million, and net cash used of ~$5.7 million.
Positive
- EXOZ position valued at approximately $30 million
- Paulex completed a $19 million seed round, fully funding development
- Year-end liquidity of approximately $22.3 million in cash and marketable securities
Negative
- Net cash used in 2025 of approximately $5.7 million
- Annual fixed operating expenses of approximately $10 million, including $4 million invested in MDB Direct and PatentVest
Key Figures
Market Reality Check
Peers on Argus
MDBH slipped 1.67% while peers were mixed: PLUT up 0.99%, GREE/COHN/GRYP/SLNH down between 3–7%. Only COHN appeared in momentum scans, also moving down, pointing to stock-specific rather than broad sector drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Earnings call notice | Positive | +4.8% | Announcement of scheduled webinar to discuss Q4 and full-year 2025 results. |
| Mar 11 | IP collaboration | Positive | -4.0% | PatentVest strategic IP engagement with Porosome Therapeutics on secretory disorders. |
| Feb 26 | Research report | Neutral | -1.3% | PatentVest report on oral small-molecule GLP-1 patent race and market landscape. |
| Feb 02 | Board changes | Positive | -3.1% | Appointment of new director and departure of long-serving board member. |
| Jan 14 | Research report | Positive | +6.7% | PatentVest report on patent landscape in the $1.8 trillion space economy. |
Recent history shows mixed reactions: some positive or neutral announcements led to gains, while other seemingly constructive updates coincided with selloffs, indicating inconsistent news-to-price alignment.
Over the last few months, MDBH has issued a series of updates spanning webinars, IP collaborations, research reports, and governance changes. A webinar announcement on Mar 23, 2026 ahead of results saw the stock rise 4.78%, while a strategic IP collaboration on Mar 11, 2026 coincided with a -4% move. Earlier PatentVest reports on GLP-1 and the space economy produced modest moves, and a board transition on Feb 1, 2026 saw a -3.13% reaction. Today’s full-year update fits into this pattern of frequent strategic and informational disclosures.
Market Pulse Summary
This announcement outlines MDBH’s 2025 results and strategy, emphasizing key holdings like an eXoZymes stake valued at about $30 million, a fully funded $19 million seed round for Paulex Bio, and year-end liquidity of roughly $22.3 million. It also discloses fixed operating expenses near $10 million and net cash use of $5.7 million. Investors following this story may focus on execution of planned spin-outs, capital efficiency, and progress toward the targeted Paulex Bio IPO.
Key Terms
cell-free biomanufacturing medical
beta-cell regeneration medical
ipo financial
warrants financial
AI-generated analysis. Not financial advice.
Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, March 31, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining disruptive technology companies, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025.
More Detailed Information
2025 Annual Shareholder Letter HERE.
Form 10-K HERE.
Key Assets and Strategic Developments
- eXoZymes (NASDAQ: EXOZ): MDB holds approximately 4.1 million shares and warrants, valued at approximately
$30 million based on March 30, 2026 market prices. The company is advancing cell-free biomanufacturing with large, ownable opportunities and clear commercialization timelines. - Paulex Bio: Closed a
$19 million seed round during 2025, fully funding development. MDB holds approximately 7.1 million shares and warrants. Clinical trial initiation is expected later this year, with an IPO targeted for September 2026. The beta-cell regeneration platform has multi-billion-dollar potential across Type 1 and Type 2 diabetes. - PatentVest: Advancing toward spin-out as a standalone AI-enhanced IP law firm leveraging a 20-year proprietary patent database, ABS law-firm structure, and agentic AI for patent prosecution — positioned for significant value creation in the rapidly growing legal-tech sector.
- MDB Direct (Public Ventures clearing platform): In active discussions for a strategic partnership that would realize value from this rare self-clearing asset while dramatically expanding distribution reach into individual-investor channels.
- Additional equity positions were earned in HeartBeam and Buda Juice (recorded in 2026) through advisory services, positioning these small, profitable public companies for further growth.
Financial Results
- Annual fixed operating expenses ran at approximately
$10 million for 2025, which includes$4 million investment in MDB Direct/Public Ventures clearing platform and PatentVest. - Net cash used for the full year was approximately
$5.7 million . - At year-end, we also held approximately
$22.3 million in cash, current assets, marketable securities less all liabilities - The Company is targeting improved cost/scale efficiencies as PatentVest and MDB Direct/Public Venture are spun off as independent entities.
Fourth Quarter and Full Year 2025 Results Zoom Webinar at 4:30 p.m. ET Today
Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.
Investors can register now for the Zoom webinar HERE. The live webinar can also be accessed on the day of the event through MDB’s investor relations website at https://investors.mdb.com/.
About MDB Capital Holdings, LLC
Founded in 1997, MDB Capital focuses on launching category-defining disruptive technology companies through a unique public venture capital platform and approach. The firm emphasizes community-driven financings of early-stage leaders in significant business and technology categories via early public offerings, primarily on NASDAQ, as well as post-IPO offerings for qualifying companies. MDB Capital Holdings, LLC (NASDAQ: MDBH) and its subsidiaries—including MDB Capital, a venture-focused broker-dealer with the MDB Direct trading platform, and PatentVest, the first integrated IP strategy and law firm—operate under the MDB Capital brand. MDB Capital is a registered broker-dealer, Member FINRA/SIPC. For more information, please visit www.mdb.com
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MDB's control. MDB's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in documents that may be filed by MDB from time to time with the SEC. The forward-looking statements included in this press release represent MDB's views as of the date of this press release. MDB anticipates that subsequent events and developments will cause its views to change. MDB undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing MDB's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
IR@mdb.com
Media Contact:
press@mdb.com
FAQ
What did MDBH announce in the March 31, 2026 2025 full-year update?
What was MDBH's cash position and cash usage for 2025 (MDBH)?
Which material asset holdings did MDBH report as of March 30, 2026?
What near-term milestones and timelines did MDBH disclose for portfolio companies?
